Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer

Rebecca Swan, Abdo Alnabulsi, Beatriz Cash, Ayham Alnabulsi, Graeme I. Murray*

*Corresponding author for this work

Research output: Contribution to journalArticle

15 Citations (Scopus)
4 Downloads (Pure)

Abstract

Oxysterols are oxidised derivatives of cholesterol, formed by the enzymatic activity of several cytochrome P450 enzymes and tumour-derived oxysterols have been implicated in tumour growth and survival. The aim of this study was to profile the expression of oxysterol metabolising enzymes in primary colorectal cancer and assess the association between expression and prognosis. Immunohistochemistry was performed on a colorectal cancer tissue microarray containing 650 primary colorectal cancers using monoclonal antibodies to CYP2R1, CYP7B1, CYP8B1, CYP27A1, CYP39A1, CYP46A1 and CYP51A1, which we have developed. Unsupervised hierarchical cluster analysis was used to examine the overall relationship of oxysterol metabolising enzyme expression with outcome and based on this identify an oxysterol metabolising enzyme signature associated with prognosis. Cluster analysis of the whole patient cohort identified a good prognosis group (mean survival=146 months 95% CI 127-165 months) that had a significantly better survival (χ2=12.984, p<0.001, HR=1.983, 95% CI 1.341-2.799) than the poor prognosis group (mean survival=107 months, 95% CI 98-123 months). For the mismatch repair proficient cohort, the good prognosis group had a significantly better survival (χ2=8.985, p=0.003, HR=1.845, 95% CI 1.227-2.774) than the poor prognosis group. Multi-variate analysis showed that cluster group was independently prognostically significant in both the whole patient cohort (p=0.02, HR=1.554, 95% CI 1.072-2.252) and the mismatch repair proficient group (p=0.04, HR=1.530, 95% CI 1.014-2.310). Individual oxysterol metabolising enzymes are overexpressed in colorectal cancer and an oxysterol metabolising enzyme expression profile associated with prognosis has been identified in the whole patient cohort and in mismatch repair proficient colorectal cancers.
Original languageEnglish
Article number10224
Pages (from-to)46509-46527
Number of pages19
JournalOncotarget
Volume7
Issue number29
DOIs
Publication statusPublished - 22 Jun 2016

Keywords

  • biomarker
  • colorectal cancer
  • cytochrome P450
  • oxysterol
  • prognosis
  • BREAST-CANCER
  • TUMOR-GROWTH
  • MATRIX METALLOPROTEINASES
  • EXPRESSION
  • CHOLESTEROL
  • THERAPY
  • PROGRESSION
  • METASTASIS
  • CYP1B1
  • IDENTIFICATION

Cite this

Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer. / Swan, Rebecca; Alnabulsi, Abdo; Cash, Beatriz; Alnabulsi, Ayham; Murray, Graeme I.

In: Oncotarget, Vol. 7, No. 29, 10224, 22.06.2016, p. 46509-46527.

Research output: Contribution to journalArticle

@article{316e305f7f0e49e4b3d38772b11796b8,
title = "Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer",
abstract = "Oxysterols are oxidised derivatives of cholesterol, formed by the enzymatic activity of several cytochrome P450 enzymes and tumour-derived oxysterols have been implicated in tumour growth and survival. The aim of this study was to profile the expression of oxysterol metabolising enzymes in primary colorectal cancer and assess the association between expression and prognosis. Immunohistochemistry was performed on a colorectal cancer tissue microarray containing 650 primary colorectal cancers using monoclonal antibodies to CYP2R1, CYP7B1, CYP8B1, CYP27A1, CYP39A1, CYP46A1 and CYP51A1, which we have developed. Unsupervised hierarchical cluster analysis was used to examine the overall relationship of oxysterol metabolising enzyme expression with outcome and based on this identify an oxysterol metabolising enzyme signature associated with prognosis. Cluster analysis of the whole patient cohort identified a good prognosis group (mean survival=146 months 95{\%} CI 127-165 months) that had a significantly better survival (χ2=12.984, p<0.001, HR=1.983, 95{\%} CI 1.341-2.799) than the poor prognosis group (mean survival=107 months, 95{\%} CI 98-123 months). For the mismatch repair proficient cohort, the good prognosis group had a significantly better survival (χ2=8.985, p=0.003, HR=1.845, 95{\%} CI 1.227-2.774) than the poor prognosis group. Multi-variate analysis showed that cluster group was independently prognostically significant in both the whole patient cohort (p=0.02, HR=1.554, 95{\%} CI 1.072-2.252) and the mismatch repair proficient group (p=0.04, HR=1.530, 95{\%} CI 1.014-2.310). Individual oxysterol metabolising enzymes are overexpressed in colorectal cancer and an oxysterol metabolising enzyme expression profile associated with prognosis has been identified in the whole patient cohort and in mismatch repair proficient colorectal cancers.",
keywords = "biomarker, colorectal cancer, cytochrome P450, oxysterol, prognosis, BREAST-CANCER, TUMOR-GROWTH, MATRIX METALLOPROTEINASES, EXPRESSION, CHOLESTEROL, THERAPY, PROGRESSION, METASTASIS, CYP1B1, IDENTIFICATION",
author = "Rebecca Swan and Abdo Alnabulsi and Beatriz Cash and Ayham Alnabulsi and Murray, {Graeme I.}",
note = "ACKNOWLEDGMENTS The immunohistochemistry was performed with the support of the Grampian Biorepository. GRANT SUPPORT Rebecca Swan was supported by the Jean Shanks Foundation. This study was supported by funding from Friends of Anchor and the Encompass kick start and SMART:Scotland award schemes of Scottish Enterprise.",
year = "2016",
month = "6",
day = "22",
doi = "10.18632/oncotarget.10224",
language = "English",
volume = "7",
pages = "46509--46527",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "29",

}

TY - JOUR

T1 - Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer

AU - Swan, Rebecca

AU - Alnabulsi, Abdo

AU - Cash, Beatriz

AU - Alnabulsi, Ayham

AU - Murray, Graeme I.

N1 - ACKNOWLEDGMENTS The immunohistochemistry was performed with the support of the Grampian Biorepository. GRANT SUPPORT Rebecca Swan was supported by the Jean Shanks Foundation. This study was supported by funding from Friends of Anchor and the Encompass kick start and SMART:Scotland award schemes of Scottish Enterprise.

PY - 2016/6/22

Y1 - 2016/6/22

N2 - Oxysterols are oxidised derivatives of cholesterol, formed by the enzymatic activity of several cytochrome P450 enzymes and tumour-derived oxysterols have been implicated in tumour growth and survival. The aim of this study was to profile the expression of oxysterol metabolising enzymes in primary colorectal cancer and assess the association between expression and prognosis. Immunohistochemistry was performed on a colorectal cancer tissue microarray containing 650 primary colorectal cancers using monoclonal antibodies to CYP2R1, CYP7B1, CYP8B1, CYP27A1, CYP39A1, CYP46A1 and CYP51A1, which we have developed. Unsupervised hierarchical cluster analysis was used to examine the overall relationship of oxysterol metabolising enzyme expression with outcome and based on this identify an oxysterol metabolising enzyme signature associated with prognosis. Cluster analysis of the whole patient cohort identified a good prognosis group (mean survival=146 months 95% CI 127-165 months) that had a significantly better survival (χ2=12.984, p<0.001, HR=1.983, 95% CI 1.341-2.799) than the poor prognosis group (mean survival=107 months, 95% CI 98-123 months). For the mismatch repair proficient cohort, the good prognosis group had a significantly better survival (χ2=8.985, p=0.003, HR=1.845, 95% CI 1.227-2.774) than the poor prognosis group. Multi-variate analysis showed that cluster group was independently prognostically significant in both the whole patient cohort (p=0.02, HR=1.554, 95% CI 1.072-2.252) and the mismatch repair proficient group (p=0.04, HR=1.530, 95% CI 1.014-2.310). Individual oxysterol metabolising enzymes are overexpressed in colorectal cancer and an oxysterol metabolising enzyme expression profile associated with prognosis has been identified in the whole patient cohort and in mismatch repair proficient colorectal cancers.

AB - Oxysterols are oxidised derivatives of cholesterol, formed by the enzymatic activity of several cytochrome P450 enzymes and tumour-derived oxysterols have been implicated in tumour growth and survival. The aim of this study was to profile the expression of oxysterol metabolising enzymes in primary colorectal cancer and assess the association between expression and prognosis. Immunohistochemistry was performed on a colorectal cancer tissue microarray containing 650 primary colorectal cancers using monoclonal antibodies to CYP2R1, CYP7B1, CYP8B1, CYP27A1, CYP39A1, CYP46A1 and CYP51A1, which we have developed. Unsupervised hierarchical cluster analysis was used to examine the overall relationship of oxysterol metabolising enzyme expression with outcome and based on this identify an oxysterol metabolising enzyme signature associated with prognosis. Cluster analysis of the whole patient cohort identified a good prognosis group (mean survival=146 months 95% CI 127-165 months) that had a significantly better survival (χ2=12.984, p<0.001, HR=1.983, 95% CI 1.341-2.799) than the poor prognosis group (mean survival=107 months, 95% CI 98-123 months). For the mismatch repair proficient cohort, the good prognosis group had a significantly better survival (χ2=8.985, p=0.003, HR=1.845, 95% CI 1.227-2.774) than the poor prognosis group. Multi-variate analysis showed that cluster group was independently prognostically significant in both the whole patient cohort (p=0.02, HR=1.554, 95% CI 1.072-2.252) and the mismatch repair proficient group (p=0.04, HR=1.530, 95% CI 1.014-2.310). Individual oxysterol metabolising enzymes are overexpressed in colorectal cancer and an oxysterol metabolising enzyme expression profile associated with prognosis has been identified in the whole patient cohort and in mismatch repair proficient colorectal cancers.

KW - biomarker

KW - colorectal cancer

KW - cytochrome P450

KW - oxysterol

KW - prognosis

KW - BREAST-CANCER

KW - TUMOR-GROWTH

KW - MATRIX METALLOPROTEINASES

KW - EXPRESSION

KW - CHOLESTEROL

KW - THERAPY

KW - PROGRESSION

KW - METASTASIS

KW - CYP1B1

KW - IDENTIFICATION

U2 - 10.18632/oncotarget.10224

DO - 10.18632/oncotarget.10224

M3 - Article

C2 - 27341022

VL - 7

SP - 46509

EP - 46527

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 29

M1 - 10224

ER -